Edition:
India

Skyhawk Therapeutics Signs Agreement With Genentech To Develop Small Molecule RNA Splicing Modifiers For Oncology And Neurodegenerative Diseases


Tuesday, 16 Jul 2019 

July 16 (Reuters) - Roche Holding AG ::SKYHAWK THERAPEUTICS ANNOUNCES AGREEMENT WITH GENENTECH TO DISCOVER AND DEVELOP SMALL MOLECULE RNA SPLICING MODIFIERS FOR ONCOLOGY AND NEURODEGENERATIVE DISEASES.SKYHAWK THERAPEUTICS - SKYHAWK WILL RECEIVE AN UPFRONT PAYMENT AND MAY BE ELIGIBLE FOR MORE THAN $2 BILLION OVER TIME.SKYHAWK THERAPEUTICS - WILL USE SKYSTAR PLATFORM TO DEVELOP DRUG CANDIDATES DIRECTED TO MULTIPLE TARGETS FOR ONCOLOGY AND NEURODEGENERATIVE DISEASES.SKYHAWK THERAPEUTICS - AGREEMENT GRANTS GENENTECH AN EXCLUSIVE WORLDWIDE LICENSE TO DEVELOP AND COMMERCIALIZE POTENTIAL THERAPEUTICS.SKYHAWK THERAPEUTICS - GENENTECH WILL BE RESPONSIBLE FOR CLINICAL DEVELOPMENT AND COMMERCIALIZATION..SKYHAWK - DEAL ALSO INCLUDES ROYALTIES ON SALES OF COMMERCIALIZED MEDICINES.